Ubiquitin Ligase (E3) Inhibitors

Ubiquitin ligase (E3) inhibitors are a class of compounds that have emerged as significant tools in the study of ubiquitin-proteasome system regulation These inhibitors selectively bind to and inhibit the activity of E3 ligases enzymes responsible for the transfer of ubiquitin molecules to target proteins thus preventing their degradation by the proteasome By modulating the activity of E3 ligases these inhibitors offer researchers a powerful means to investigate the roles of specific ubiquitin-dependent processes and pathways in cellular function and disease Moreover as the ubiquitin-proteasome system plays a crucial role in maintaining protein homeostasis and regulating cellular processes such as cell cycle progression DNA repair and signal transduction the development of E3 ligase inhibitors holds great potential for targeted therapies in various diseases including cancer and neurodegenerative disorders Our company offers a diverse range of high-quality potent E3 ligase inhibitors to support your research endeavors

Catalog Number	Chemical Name	CAS #	Price
BC-0070	NSC 146109 hydrochloride	59474-01-0	Online Inquiry
EI-0022	(±)-Thalidomide	50-35-1	Online Inquiry
EI-0452	BRD-5529	1358488-78-4	Online Inquiry
EI-1188	Iberdomide	1323403-33-3	Online Inquiry
EI-1591	NSC 66811	6964-62-1	Online Inquiry
EI-1598	NSC-687852	1009817-63-3	Online Inquiry
EI-1820	PRT4165	31083-55-3	Online Inquiry
EI-2022	SKPin C1	432001-69-9	Online Inquiry
EI-2028	SMER-3	67200-34-4	Online Inquiry

Application

Ubiquitin Ligase (E3) inhibitors offer a wide range of applications across various fields In the field of drug discovery and development these inhibitors are crucial tools for understanding the mechanisms of protein degradation and identifying potential therapeutic targets By blocking the activity of specific E3 ligases researchers can investigate the roles of targeted proteins in disease processes and explore the potential of developing drugs that modulate protein degradation pathways

In the field of cancer research Ubiquitin Ligase (E3) inhibitors have shown promise as potential anti-cancer agents Certain E3 ligases are known to be overexpressed in various types of cancers leading to increased protein degradation and abnormal cell growth By inhibiting these E3 ligases it is possible to disrupt the degradation of tumor suppressor proteins and potentially halt the progression of cancer

Furthermore Ubiquitin Ligase (E3) inhibitors have also been explored as therapeutic options for neurodegenerative diseases Dysfunction in protein degradation pathways has been implicated in the pathogenesis of disorders such as Alzheimer's and Parkinson's disease By targeting specific E3 ligases involved in the degradation of disease-associated proteins researchers aim to prevent the accumulation and aggregation of these proteins potentially slowing down or halting disease progression

Overall Ubiquitin Ligase (E3) inhibitors offer a promising avenue for research and drug development in various fields including cancer neurodegenerative diseases and beyond Their ability to modulate protein degradation pathways opens up new possibilities for understanding disease mechanisms and developing novel therapeutic strategies

Please note that all services are for research use only. Not intended for any clinical use.

Ubiquitin Ligase (E3) Inhibitors